PMID: 8472720Apr 1, 1993Paper

The effect of verapamil on major events in patients with impaired cardiac function recovering from acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction

European Heart Journal
C M Jespersen

Abstract

In the Danish Verapamil Infarction Trial II (DAVIT II) intervention with verapamil significantly decreased the first major event rate (i.e. reinfarction or death) in patients recovering from acute myocardial infarction. As calcium channel antagonists might have a detrimental effect in patients with heart failure, the effect of verapamil on major events in patients with and without impaired left ventricular function was analysed. Eight hundred and seventy-eight patients were randomized to verapamil 120 mg t.i.d. and 897 to placebo. Patients were followed up to 18 months. The endpoint was the first major event while on trial medication. In patients treated for heart failure during the acute phase of myocardial infarction, the lowest 18-month event rate was seen in the verapamil group (21.2% vs 22.2%) (absolute numbers: events/patients verapamil 47/291; placebo 60/323) (ns). Similarly, in patients treated with diuretics at randomization, the lowest 18-month event rate was seen in those randomized to verapamil (22.4 vs 24.3%) (absolute numbers: events/patients verapamil 57/349; placebo 76/375 (ns). When patients were subdivided according to New York Heart Association functional classes, verapamil reduced the event rate in all class...Continue Reading

Citations

Nov 5, 1999·The New England Journal of Medicine·D R Abernethy, J B Schwartz
Jun 1, 1995·Disease-a-month : DM·S M Smith
Oct 10, 2009·Circulation Research·Marvin G ChangM Roselle Abraham
Oct 16, 1999·Proceedings of the Association of American Physicians·J P ClozelS I Ertel
Mar 1, 1997·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·J F HansenO Pedersen-Bjergaard
Mar 3, 1998·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·J P ClozelS I Ertel

❮ Previous
Next ❯